If you lead an FQHC, 340B pharmacy, finance department, or compliance program, the 2027 rebate model timeline deserves your attention now: not after the first affected claim is rejected.

Under the revised framework announced by the Health Resources and Services Administration (HRSA), qualifying manufacturers may use rebates instead of upfront 340B discounts for a limited group of drugs associated with the Medicare Drug Price Negotiation Program. The earliest effective date is January 1, 2027.

That date is confirmed. Many operational details around manufacturer plans, platform onboarding, claim validation, and future legislative action remain subject to change.

This guide separates confirmed events from expected milestones so your entity can prepare without treating proposals as final requirements.

Disclaimer: The 340B Rebate Model Pilot, manufacturer participation, implementation requirements, and legislative proposals may change. This article is for educational purposes only and is not legal, accounting, regulatory, or compliance advice. Your entity should review current HRSA materials and obtain advice appropriate to its circumstances.

The 340B Rebate Model Timeline at a Glance

Date or period	Status	What it means
July 31–August 1, 2025	Confirmed historical event	HRSA announced the original rebate model pilot.
September 15, 2025	Confirmed historical deadline	Manufacturer applications for the original pilot were due.
October 30, 2025	Confirmed historical event	HRSA announced approval of eight manufacturer applications.
December 29, 2025	Confirmed historical event	A federal court issued a nationwide preliminary injunction affecting the original pilot.
February 10, 2026	Confirmed historical event	The original pilot notice and manufacturer approvals were vacated and remanded.
February 17, 2026	Confirmed historical event	HRSA issued a Request for Information on a potential revised model.
July 31–August 3, 2026	Confirmed current event	HRSA published the revised pilot notice.
August 24, 2026	Confirmed deadline	Eligible manufacturers must submit plans to HRSA.
September 24, 2026	HRSA target	Approvals, if any, are expected by this date.
January 1, 2027	Confirmed earliest effective date	Approved plans may begin for eligible selected drugs.
April 30, 2028	Confirmed evaluation milestone	HRSA intends to publish an evaluation after the first year of pilot operations.

What Has Happened So Far?

July–August 2025: The original pilot was announced

HRSA first announced a voluntary 340B rebate model pilot for manufacturers with Medicare Drug Price Negotiation Program agreements covering selected drugs for initial price applicability year 2026.

The original pilot was designed to begin on January 1, 2026. It would have required covered entities to purchase certain drugs at wholesale acquisition cost (WAC), submit claims-level data, and receive the 340B value later through a rebate.

Manufacturers submitted applications by September 15, 2025. HRSA announced approvals for eight manufacturers on October 30 and later approved a ninth manufacturer with an April 1, 2026 effective date.

December 2025–February 2026: Litigation halted the original pilot

Covered entity stakeholders challenged the original pilot. On December 29, 2025, a federal court issued a preliminary injunction that prevented implementation.

HHS later dismissed its appeal, withdrew the original pilot, and the court formally vacated and remanded the original notice and manufacturer approvals on February 10, 2026.

For your entity, the operational lesson is important: a published implementation date does not eliminate legal or administrative uncertainty. Your readiness plan should be flexible enough to adapt when HRSA revises guidance or a court affects implementation.

February 2026: HRSA requested stakeholder input

On February 17, 2026, HRSA issued a Request for Information seeking feedback about whether and how to implement a rebate approach. The agency asked stakeholders to address:

Cash-flow impact.
Administrative burden.
Claims-level data requirements.
Duplicate-discount prevention.
Data security and privacy.
Manufacturer validation and denial processes.
The role of technology platforms.
Reliance interests tied to the traditional upfront discount model.

HRSA reported receiving extensive stakeholder feedback, including comments from FQHCs, hospitals, manufacturers, pharmacies, technology companies, and advocacy organizations.

July–August 2026: The Revised Pilot Materials

HRSA published the revised 340B Rebate Model Pilot notice in late July and early August 2026. The revised framework is narrower than the original pilot.

The pilot is limited to the NDC-11s of selected drugs for initial price applicability years 2026 and 2027 that appear on the CMS Medicare Drug Price Negotiation Selected Drug List. The selected drugs are included regardless of payer or indication, but only during their applicable Medicare price applicability periods.

HRSA estimates that the included products represent less than 5.5% of total 2025 340B sales volume. That means most 340B purchasing is expected to remain under the traditional upfront discount model in 2027.

The revised materials require manufacturer plans to address several operational areas:

The technology platform used for data submission.
Security and privacy protections.
At least 90 days’ notice to affected covered entities.
Existing distribution mechanisms, such as wholesaler accounts with WAC prices loaded.
Technical assistance and manufacturer points of contact.
Claims submission and reconciliation reporting.
Quarterly 340B price files.
Rebate payment or documented denial.
Reporting to HRSA about claims, denials, and pilot performance.

The revised pilot also limits the claims data that manufacturers may request. Pharmacy fields include items such as date of service, date prescribed, prescription number, fill number, NDC-11, quantity, prescriber ID, service provider ID, 340B ID, BIN, and PCN. Medical claim fields include date of service, claim number, NDC-11, units, provider identifiers, 340B ID, and health plan information.

The notice states that purchasing data and encounter data should not be requested as part of the pilot at this time.

Professionals reviewing compliance documents for 340B rebate model implementation

August–September 2026: Manufacturer Submission and Approval

August 24, 2026, is the manufacturer plan submission deadline. Eligible manufacturers must submit plans to HRSA at 340BPricing@hrsa.gov.

HRSA expects to make approval decisions by September 24, 2026. This is an expected agency milestone, not a guarantee that every submitted plan will be approved.

Manufacturer participation is voluntary. However, once HRSA approves a manufacturer’s plan, the rebate process may become mandatory for covered entities acquiring that manufacturer’s affected drugs.

Approved manufacturers must provide at least 90 calendar days’ notice before implementation. The notice should include information about affected drugs, platform registration, purchasing procedures, data submission, and other operational requirements.

Your entity should not wait for a manufacturer email to begin planning. Start by identifying:

Selected drugs on your formulary.
Manufacturer and NDC-11 exposure.
In-house and contract pharmacy volume.
Wholesaler account configuration.
TPA and pharmacy system capabilities.
Medicaid billing and duplicate-discount controls.
Expected WAC-to-340B cash exposure.

Review 2027 340B Rebate Model Requirements: What Covered Entities Need to Prepare for a more detailed preparation checklist.

January 1, 2027: Earliest Pilot Effective Date

January 1, 2027, is the earliest effective date for approved rebate plans under the revised pilot.

For affected transactions, the expected workflow is:

Your entity purchases the selected drug at WAC.
The drug is dispensed or administered to an eligible patient.
Required claims-level information is submitted.
The platform and manufacturer validate the submission.
The manufacturer pays the rebate or provides a documented denial.
Your entity reconciles the transaction with pharmacy, wholesaler, vendor, and general ledger records.

Covered entities must generally be permitted at least 45 calendar days from the date of dispense to submit the required information. Your entity should use a daily or near-daily process rather than relying on a month-end batch.

The manufacturer must pay or deny a complete claim within 10 calendar days. If the submission is incomplete, the payment clock restarts after the required information is provided.

The revised framework also contemplates:

Real-time reconciliation reports.
Quarterly 340B price files.
Unit-level rebate payments.
A 15-day implementation grace period for certain unreplenished accumulations.
Documented denial reasons.
A process for challenging denials.

340B claims dashboard showing approved, rejected, and pending claim statuses

2027: What FQHC Teams Should Monitor

Finance and CFO teams

Your finance team should monitor:

WAC purchases before rebate receipt.
Rebate accounts receivable.
Days between dispense, submission, approval, and payment.
Denial rates and unresolved balances.
Credit-line and days-cash-on-hand impact.
General ledger treatment and month-end accruals.

Read 340B Rebate Model Readiness: The Proven Framework for Managing Cash Flow Volatility for a cash-flow planning framework.

Pharmacy leaders

Pharmacy teams should validate:

Affected NDC-11s and package sizes.
Inventory and replenishment procedures.
Dispense-date and submission-date logic.
Reversals and rebills.
In-house and contract pharmacy workflows.
Patient access risks if a claim is delayed or denied.

IT and data teams

IT teams should test:

Data mapping from pharmacy and medical systems.
TPA file completeness.
Secure data transmission.
Platform registration and user access.
Exception reporting.
Duplicate records and unmatched claims.
Backup procedures if a platform is unavailable.

GapRx’s 340B Analytics and Program Dashboards can help consolidate claims, financial, vendor, and exception reporting into a clearer management view.

Compliance teams

Compliance leaders should monitor:

Patient eligibility and diversion controls.
Medicaid duplicate-discount policies.
Manufacturer notices and approved plans.
Documentation retention.
Denial trends.
HIPAA and data-security safeguards.
Internal audit results and corrective actions.

GapRx provides HRSA Audit and 340B Compliance support to help entities maintain organized documentation and audit-ready controls.

Legislative Developments: SECURE and SUSTAIN

The future of the rebate model is also connected to Congress.

The SECURE 340B Act, introduced in the House as H.R. 9599, is a pending proposal. Among other provisions, it would require upfront 340B discounts for a period of time and establish a clearinghouse structure. It is not enacted law.

The SUSTAIN 340B Act, introduced in the Senate on August 5, 2026, would terminate the HRSA rebate pilot within one year of enactment and prohibit expansion of the pilot or a substantially similar model. It would also establish a national data clearinghouse and add new transparency, reporting, and oversight provisions.

Neither bill should be treated as a final 2027 requirement. Monitor Congress.gov, HRSA, CMS, and trusted 340B policy sources for changes.

What Happens After 2027?

HRSA intends to monitor submissions, payments, denials, disputes, administrative burden, data quality, and duplicate-discount prevention throughout the pilot.

The revised notice states that HRSA intends to publish an evaluation by April 30, 2028, after the first year of pilot operations.

That evaluation may influence whether the model is modified, expanded, limited, or replaced. Your entity should therefore build adaptable controls rather than create a one-time project that assumes the 2027 process will remain unchanged.

Final Takeaway

The 340B rebate model timeline has moved from proposal to a potentially operational pilot with a January 1, 2027 effective date.

For your FQHC, the immediate priorities are clear:

Identify affected drugs and manufacturers.
Model WAC-related cash exposure.
Validate claims data and submission workflows.
Confirm vendor and platform responsibilities.
Build payment and denial tracking.
Strengthen reconciliation and audit documentation.
Monitor HRSA guidance and legislative developments.

Read How the 340B Rebate Model Works: A Guide for Covered Entities for the underlying payment mechanics, then contact GapRx to evaluate your entity’s readiness, financial exposure, and operational controls.

340B Rebate Model Timeline: Key Dates, Pilots, and What to Watch in 2027